A Poll of Cancer Myths vs. Facts: Tell Us What You Think

The investigational drug ziftomenib is currently being evaluated for patients with relapsed/refractory NPM1-mutant acute myeloid leukemia.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

A treatment combination of Anktiva and Bacillus Calmette-Guérin was approved by the FDA for certain patients with non-muscle-invasive bladder cancer.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

Patient/provider trust, education and lifestyle choices are crucial as Black men face higher incidence and mortality in prostate cancer, experts said.

What it’s like having a “second birthday” after receiving a bone marrow transplant for my AML.